16.25 USD
▲+0.09+0.56%
盘后 16.00 -1.54%
2026-09-15
市值
$5.68B
市盈率
—
EPS
-0.97
股息率
—
52 周区间
1.53 – 24.28
成交量
4.69M
Beta
0.65
目标价
24.11
52W 低 1.5352W 高 24.28
价格走势
公司简介
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agre...